Amedeo Smart

Free Medical Literature Service

 

Amedeo

Drug Resistance
  Free Subscription

Articles published in
Clin Infect Dis
    July 2026
  1. DAS S, Singh S, Tawde Y, Spruijtenburg B, et al
    Trends in Antifungal Resistance and Mechanistic Insights Into Azole Resistance in Candida (Candidozyma) auris: A 13-Year Study of a Comprehensive Set of Clinical Isolates From India.
    Clin Infect Dis. 2026;83:89-99.
    >> Share

  2. CROSS GB, Walker HN, Hasan T, Berry C, et al
    We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness.
    Clin Infect Dis. 2026;82:e1326-e1332.
    >> Share

    June 2026
  3. BAVARO DF, Belati A, Sacchet D, Cilli A, et al
    Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Cephalosporins Plus Daptomycin as Initial Therapy for MRSA Bacteremia: Does a "Hit Hard and Fast" Strategy Improve Outcomes?
    Clin Infect Dis. 2026 Jun 9:ciag228. doi: 10.1093.
    >> Share

  4. MANESH A, Aslan AT, Mohan George M, Sulaiman H, et al
    Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the World.
    Clin Infect Dis. 2026;82.
    >> Share

  5. PATERSON DL
    Advancing Clinical Evidence in Infectious Diseases: An Infectious Diseases Clinical Trials Network for Asia, the "Antimicrobial Resistance Hot Zone".
    Clin Infect Dis. 2026;82.
    >> Share

  6. ALIGUI AF, Hor SW, Blanco-Arevalo A, Gupta A, et al
    Challenges to Accessing Newer Antibiotics for Multidrug-resistant Bacterial Infections in Asia: A Literature Review of Multi-Stakeholder Perspectives.
    Clin Infect Dis. 2026;82.
    >> Share

    April 2026
  7. SARAVOLATZ L, Gandhi TN, Vaughn VM, Ratz D, et al
    Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia.
    Clin Infect Dis. 2026;82:648-657.
    >> Share

  8. MO Y
    Transforming Antimicrobial Resistance Diagnostics From Conceptual Priority to Operational Reality.
    Clin Infect Dis. 2026 Apr 29:ciag021. doi: 10.1093.
    >> Share

  9. LAMB G, Pallett SJC, Charani E, Kanu EM, et al
    Assessment of the Prioritization of Diagnostics in National Action Plans for Antimicrobial Resistance.
    Clin Infect Dis. 2026 Apr 29:ciag020. doi: 10.1093.
    >> Share

  10. BROWN KA, Daneman N
    Is Time to Appropriate Therapy a Mediator of Mortality Associated With Antimicrobial Resistance?
    Clin Infect Dis. 2026 Apr 9:ciag090. doi: 10.1093.
    >> Share

  11. THORPE A, Lee RA, Szymczak JE, Farrell MC, et al
    Comparing the Antimicrobial Resistance Crisis to the Coronavirus Disease 2019 Pandemic: A Randomized Public Health Messaging Experiment.
    Clin Infect Dis. 2026 Apr 8:ciag110. doi: 10.1093.
    >> Share

  12. MO F, Xu Y, Song Z
    Task Relatedness and Calibration Benefits in Multi-task Learning for Antimicrobial Resistance Prediction.
    Clin Infect Dis. 2026 Apr 7:ciag230. doi: 10.1093.
    >> Share

    March 2026
  13. RINALDI M, Miani B, Gibertoni D, Di Chiara M, et al
    Targeted peri-operative prophylaxis in patients colonized with Carbapenem Resistant Enterobacterales undergoing Liver Transplantation: a multinational cohort study.
    Clin Infect Dis. 2026 Mar 25:ciag185. doi: 10.1093.
    >> Share

  14. CASTILLO AY, Jenkins TC, Axelrath S, Barocas JA, et al
    Street Stewardship: The next frontier to address antibiotic resistance and health inequities.
    Clin Infect Dis. 2026 Mar 21:ciag177. doi: 10.1093.
    >> Share

  15. BOUILLER K, Cella E, Jacko NF, Hiehle ME, et al
    Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection.
    Clin Infect Dis. 2026;82:402-410.
    >> Share

  16. MARTIN MA, Blenkinsop A, Moffa M, Reynolds SJ, et al
    Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study.
    Clin Infect Dis. 2026 Mar 13:ciag161. doi: 10.1093.
    >> Share

  17. KHADER K, Haroldsen C, Stevens V, Visnovsky L, et al
    Estimating changes in facility MRSA infection rates due to changes in MRSA precaution policy.
    Clin Infect Dis. 2026 Mar 13:ciag176. doi: 10.1093.
    >> Share

  18. MAZZITELLI M, Parczewski M, Burger D, Wensing A, et al
    Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.
    Clin Infect Dis. 2026 Mar 11:ciag046. doi: 10.1093.
    >> Share

    February 2026
  19. CANTON R, Lim AN, Cortes V, Diaz-Reganon J, et al
    Uncomplicated Urinary Tract Infections: From an Invisible Impact to a Visible Change in Complex Care.
    Clin Infect Dis. 2026 Feb 25:ciaf705. doi: 10.1093.
    >> Share

  20. MITCHELL KK, Smith AC, Ayala JC, Schmerer MW, et al
    Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae.
    Clin Infect Dis. 2026;82.
    >> Share

  21. STERKEL AK, Loya TJ, Smith AC, Southern T, et al
    Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods.
    Clin Infect Dis. 2026;82.
    >> Share

  22. GREEN AS, Li JZ, Sax PE
    Is Two Drug Therapy with Dolutegravir and Lamivudine an Appropriate Option for People with HIV and Historic Lamivudine Resistance?
    Clin Infect Dis. 2026 Feb 10:ciag061. doi: 10.1093.
    >> Share

  23. DE LAGARDE M, De Miguel R, Sigcha MA, Blanco JL, et al
    Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results from the VOLVER Clinical Trial.
    Clin Infect Dis. 2026 Feb 10:ciag060. doi: 10.1093.
    >> Share

  24. DORAZIO AJ, Aitken SL, Pierce VM, Kline EG, et al
    First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa.
    Clin Infect Dis. 2026;82:44-48.
    >> Share

  25. ANGELINO NF, O'Hara LM, Bahr M, Newman M, et al
    Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions.
    Clin Infect Dis. 2026;82:142-144.
    >> Share

  26. MISHRIKY F, Chan PA
    Antimicrobial resistance concerns should not limit doxycycline post-exposure prophylaxis implementation for bacterial STI prevention.
    Clin Infect Dis. 2026 Feb 9:ciag075. doi: 10.1093.
    >> Share

    January 2026
  27. OLDENBURG CE, Coulibaly B, Sie A, Ouattara M, et al
    Macrolide and non-macrolide resistance after 36 months of mass azithromycin distribution in Burkina Faso: A cluster randomized trial.
    Clin Infect Dis. 2026 Jan 31:ciag051. doi: 10.1093.
    >> Share

  28. GOTO M, Bandyopadhyay A, Shi Q, Wang Y, et al
    Personalized Antibiogram: A Novel Multi-Task Machine Learning Framework for Simultaneous Prediction of Antimicrobial Resistance Profile with Enhanced Detection of Carbapenem Resistance in Enterobacteriaceae.
    Clin Infect Dis. 2026 Jan 17:ciag027. doi: 10.1093.
    >> Share

  29. MAKINSON A, Bani-Sadr F, Palich R, Montes B, et al
    Switch to BIC/TAF/FTC or DTG + TDF/FTC in virologically suppressed PWH: outcomes in real-world setting with and without tenofovir resistance.
    Clin Infect Dis. 2026 Jan 9:ciaf726. doi: 10.1093.
    >> Share

  30. ADAMSON PC, David HM, Pham LQ, Bui HTM, et al
    Cefixime for the Treatment of Neisseria gonorrhoeae Infections in a Setting With Increased Antimicrobial Resistance: A Retrospective Study in Hanoi, Vietnam.
    Clin Infect Dis. 2026;81.
    >> Share

  31. KLINE MC, Oliveira Roster K, Helekal D, Rumpler E, et al
    Comparing Strategies to Introduce Two New Antibiotics for Gonorrhea: A Modeling Study.
    Clin Infect Dis. 2026;81.
    >> Share

  32. FAGAN L, Alexander S, Fifer H
    The Invisible Tide of Neisseria gonorrhoeae Treatment Failures: A Review and Commentary.
    Clin Infect Dis. 2026;81.
    >> Share

  33. HSU KK, Ivanof C, Gallagher MC, Worrall DP, et al
    How Public Health Surveillance Systems Can Contribute to Antimicrobial Resistance Prevention: The Massachusetts Experience.
    Clin Infect Dis. 2026;81.
    >> Share

  34. VAN DER VEEN S, Sun X, Ge H, Chau TM, et al
    PenA Alleles Associated With Gonococcal Ceftriaxone Resistance in Cambodia, China, and Vietnam.
    Clin Infect Dis. 2026;81.
    >> Share

  35. MELENDEZ JH, Manabe YC
    Current and Emerging Approaches and Technologies for Rapid Detection of Neisseria gonorrhoeae Antimicrobial Resistance.
    Clin Infect Dis. 2026;81.
    >> Share

  36. ALLAN-BLITZ LT, Klausner JD
    Treatment Diversification to Address the Continued Rise of Antimicrobial Resistance in Neisseria gonorrhoeae.
    Clin Infect Dis. 2026;81.
    >> Share

  37. OBENG BM, Hutchinson J, Shaik A, Chetchotisakd P, et al
    Regional variations of rates and determinants of drug resistance mutations in people failing first-line therapy for HIV-1: a substudy from the D2EFT phase 3b/4 clinical trial.
    Clin Infect Dis. 2026 Jan 3:ciaf739. doi: 10.1093.
    >> Share

    December 2025
  38. TANDE AJ, Stevens RW, Ilges D, Lahr BD, et al
    Cumulative Antibiotic Exposure Is Associated With Ceftriaxone Resistance Among Patients With Urinary Source Gram-negative Bloodstream Infection: A Retrospective Cohort Study.
    Clin Infect Dis. 2025;81:871-878.
    >> Share

    November 2025
  39. SUZUKI J, Mizuno T, Takahashi S, Imai H, et al
    A possible increase in penicillin-resistant strains of Treponema pallidum.
    Clin Infect Dis. 2025 Nov 19:ciaf643. doi: 10.1093.
    >> Share

  40. BERCOT B, Assoumou L, Camelena F, Voitichouk C, et al
    Antimicrobial drug-resistant Neisseria gonorrhoeae (GC) infections in men using doxycycline postexposure prophylaxis. A substudy of the ANRS 174 DOXYVAC trial.
    Clin Infect Dis. 2025 Nov 10:ciaf591. doi: 10.1093.
    >> Share

  41. MACVANE SH, Moon R, David J, Rosenthal N, et al
    Microbiology Laboratory Testing Practices of Gram-Negative Bloodstream Infections With Difficult-to-Treat Resistant Phenotypes in US Hospitals.
    Clin Infect Dis. 2025;81:710-720.
    >> Share

  42. ROLLE C, Achhra A, Harbison C, Finkel D, et al
    Combined use of ibalizumab and lenacapavir for the treatment of multidrug-resistant HIV-1: A case series.
    Clin Infect Dis. 2025 Nov 3:ciaf597. doi: 10.1093.
    >> Share

    October 2025
  43. SMITH HJ, Modlin C
    CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria.
    Clin Infect Dis. 2025 Oct 16:ciaf478. doi: 10.1093.
    >> Share

  44. LEE YT, Chen SC
    Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality.
    Clin Infect Dis. 2025 Oct 10:ciaf493. doi: 10.1093.
    >> Share

    September 2025
  45. POGUE JM, Kaye KS
    Actually, it may be time to return to colistin and meropenem in some patients infected with Carbapenem-resistant A. baumannii (CRAB).
    Clin Infect Dis. 2025 Sep 26:ciaf534. doi: 10.1093.
    >> Share

  46. MARAOLO AE, Ceccarelli G
    It is time to go beyond the association between colistin and meropenem for invasive carbapenem-resistant Acinetobacter baumannii infections.
    Clin Infect Dis. 2025 Sep 26:ciaf533. doi: 10.1093.
    >> Share

  47. LLIBRE JM, Ripamonti D, Geretti AM, Martin-Iguacel R, et al
    Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens.
    Clin Infect Dis. 2025 Sep 23:ciaf471. doi: 10.1093.
    >> Share

  48. TAWEESUK A, Rattanaumpawan P, Rachakhom S, Wangchinda W, et al
    Cluster-randomized Controlled Trial of Enhanced Carbapenem-resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital.
    Clin Infect Dis. 2025 Sep 22:ciaf523. doi: 10.1093.
    >> Share

  49. BECK IA, Boyce CL, Bishop MD, Oldroyd AR, et al
    HIV resistance to dolutegravir varies with co-administered agents.
    Clin Infect Dis. 2025 Sep 2:ciaf481. doi: 10.1093.
    >> Share

    August 2025
  50. PARK SY, Takayama C, Ryu J, Sattah M, et al
    Design and evaluation of next-generation HIV genotyping for detection of resistance mutations to 28 antiretroviral drugs across five major classes including lenacapavir.
    Clin Infect Dis. 2025 Aug 19:ciaf458. doi: 10.1093.
    >> Share

  51. GIACOMELLI A, Capra N, Lolatto R, Gagliardini R, et al
    All-Cause Mortality in People with Four-Class Drug-Resistant HIV: A Matched Cohort Analysis with Data from the PRESTIGIO Registry.
    Clin Infect Dis. 2025 Aug 1:ciaf421. doi: 10.1093.
    >> Share

    July 2025
  52. HURALSKA M, Pogue JM, Rybak M, Abdul-Mutakabbir JC, et al
    The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of Patients With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens.
    Clin Infect Dis. 2025 Jul 19:ciaf398. doi: 10.1093.
    >> Share

    June 2025
  53. LU X, Jiang Y, Zhang R, Zhang Y, et al
    Epidemiologic and Bacterial Factors Facilitating Long-Term Transmission of Multidrug-Resistant Tuberculosis in Shanghai, China.
    Clin Infect Dis. 2025 Jun 18:ciaf313. doi: 10.1093.
    >> Share

  54. REDMOND SN, Cadnum JL, Jencson AL, Kaple CE, et al
    Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.
    Clin Infect Dis. 2025;80:984-991.
    >> Share

  55. DE JAGER V, Mockeliunas L, You H, Simonsson USH, et al
    A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination with Meropenem plus Amoxicillin/Clavulanate Among Adults with Rifampicin-Resistant Pulmonary Tuberculosis.
    Clin Infect Dis. 2025 Jun 2:ciaf276. doi: 10.1093.
    >> Share

    May 2025
  56. BALBUENA JP, Cordova E, Mykietiuk A, Farina J, et al
    Carbapenem-resistant Gram-negative bacilli bacteremia in Argentina (EMBARCAR): findings from a prospective, multicenter cohort study.
    Clin Infect Dis. 2025 May 20:ciaf259. doi: 10.1093.
    >> Share

  57. LOOSLI T, Moore CB, Buzaalirwa L, Byakwaga H, et al
    Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.
    Clin Infect Dis. 2025 May 20:ciaf204. doi: 10.1093.
    >> Share

  58. WINTERING A, Bonifacius A, Tischer-Zimmermann S, de Oliveira Mekonnen A, et al
    Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection.
    Clin Infect Dis. 2025 May 14:ciaf125. doi: 10.1093.
    >> Share

  59. BROWN KA, Fridman DJ, Garber GE, Johnstone J, et al
    The Burden of Antimicrobial Resistant Bacteremia in Ontario: A Population-wide Analysis of Attributable Mortality from 110 Pathogen-Antibiotic Combinations.
    Clin Infect Dis. 2025 May 13:ciaf213. doi: 10.1093.
    >> Share

  60. CHEVALIER JM, Hansen MA, Blumel B, Chuchu V, et al
    Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings.
    Clin Infect Dis. 2025 May 12:ciaf236. doi: 10.1093.
    >> Share

    April 2025
  61. GRENNAN T, Hull MW
    Responsible use of doxycycline for STI prevention includes both recognizing its benefits and planning for antimicrobial resistance monitoring.
    Clin Infect Dis. 2025 Apr 30:ciaf220. doi: 10.1093.
    >> Share

  62. HAO J, Liu X, Wang D, Hu H, et al
    Transmitted Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance Among Newly Diagnosed Individuals in 31 Provincial-Level Administrative Divisions in China in 2023: A Cross-sectional Survey.
    Clin Infect Dis. 2025 Apr 29:ciaf159. doi: 10.1093.
    >> Share

  63. BIRABAHARAN M
    Vancomycin-Resistant Enterococci-Active Perioperative Prophylaxis for Liver Transplant Patients Requires Attention to the Gut Microbiota.
    Clin Infect Dis. 2025 Apr 22:ciaf168. doi: 10.1093.
    >> Share

  64. WENSING AM, Charpentier C, Calvez V, Ceccherini-Silberstein F, et al
    Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance.
    Clin Infect Dis. 2025 Apr 3:ciaf161. doi: 10.1093.
    >> Share

    March 2025
  65. CUELLA-MARTIN I, Hakizayezu F, Ahmed A, Runyambo D, et al
    Paucibacillary tuberculosis drives the low positive predictive value of Xpert MTB/RIF Ultra for rifampicin resistance detection in low-prevalence settings.
    Clin Infect Dis. 2025 Mar 22:ciaf132. doi: 10.1093.
    >> Share

  66. ROGG L, Underwood M, Hanan N, Castillo-Mancilla JR, et al
    Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.
    Clin Infect Dis. 2025 Mar 21:ciaf135. doi: 10.1093.
    >> Share

  67. BURASTERO GJ, Wey EQ, Guidetti V, Cantergiani S, et al
    Impact of VRE-active perioperative prophylaxis in liver transplant patients colonized by Vancomycin-Resistant Enterococci.
    Clin Infect Dis. 2025 Mar 14:ciaf121. doi: 10.1093.
    >> Share

  68. CHARPENTIER C, Berzow D, Le Hingrat Q, Kaiser R, et al
    HIV-2EU - Supporting Standardized HIV-2 Drug Resistance Interpretation: an Update.
    Clin Infect Dis. 2025 Mar 12:ciaf110. doi: 10.1093.
    >> Share

  69. DE MIGUEL R, de Lagarde Sebastian M, Blanco Arevalo JL, Pinto-Martinez A, et al
    Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons with Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicentre, Phase IIA Clinical Trial.
    Clin Infect Dis. 2025 Mar 7:ciaf100. doi: 10.1093.
    >> Share

    February 2025
  70. SOGE OO, Thibault CS, Cannon CA, McLaughlin SE, et al
    Potential Impact of Doxycycline Post-Exposure Prophylaxis on Tetracycline Resistance in Neisseria gonorrhoeae and Colonization with Tetracycline-Resistant Staphylococcus aureus and Group A Streptococcus.
    Clin Infect Dis. 2025 Feb 28:ciaf089. doi: 10.1093.
    >> Share

  71. STEFANOVIC A, Alam ME, Matic N, Larnder A, et al
    Increased Severity of Multidrug-Resistant Shigella sonnei Infections in People Experiencing Homelessness.
    Clin Infect Dis. 2025;80:339-346.
    >> Share

  72. HSU AJ, Chiotos K, Heil EL, Shields RK, et al
    The Effectiveness of Newer Beta-Lactams for the Treatment of Antimicrobial-Resistant Gram-Negative Meningitis.
    Clin Infect Dis. 2025 Feb 20:ciaf071. doi: 10.1093.
    >> Share

  73. SHAH S, Kline EG, Haidar G, Squires KM, et al
    Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia.
    Clin Infect Dis. 2025;80:24-28.
    >> Share

    January 2025
  74. CHEMALY RF, Shafat T, Wald A, Kotton CN, et al
    Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical Trials.
    Clin Infect Dis. 2025 Jan 29:ciae638. doi: 10.1093.
    >> Share

  75. VENA A, Tiseo G, Falcone M, Bartalucci C, et al
    Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter Study.
    Clin Infect Dis. 2025 Jan 15:ciae603. doi: 10.1093.
    >> Share

    December 2024
  76. MONTROUGE T, Bertine M, Peytavin G, Saint Joannis T, et al
    Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy with Lenacapavir-Containing Regimen.
    Clin Infect Dis. 2024 Dec 31:ciae650. doi: 10.1093.
    >> Share

  77. PEREZ NAVARRO A, Nutt CT, Siedner MJ, McCluskey SM, et al
    Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long acting cabotegravir for HIV treatment: A meta-analysis.
    Clin Infect Dis. 2024 Dec 26:ciae631. doi: 10.1093.
    >> Share

  78. HAN WM, Solomon S, Smeaton L, Avihingsanon A, et al
    Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial.
    Clin Infect Dis. 2024 Dec 20:ciae627. doi: 10.1093.
    >> Share

  79. RAWSON JMO, Donaldson EF, O'Rear JJ, Harrington PR, et al
    Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SR.
    Clin Infect Dis. 2024 Dec 17:ciae615. doi: 10.1093.
    >> Share

  80. AUMA E, Alberts R, Derendinger B, Venter R, et al
    Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex, fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility.
    Clin Infect Dis. 2024 Dec 12:ciae614. doi: 10.1093.
    >> Share

    November 2024
  81. FERRAN E, Chan C, Sheikh N, Dedicoat M, et al
    Population-level frequency of fluoroquinolone resistance by whole-genome sequencing drug predictions in Mycobacterium tuberculosis complex isolates in England from 2017-2023.
    Clin Infect Dis. 2024 Nov 13:ciae560. doi: 10.1093.
    >> Share

    October 2024
  82. DHAR S, Jinadatha C, Kilgore PE, Henig O, et al
    Lowering the Acquisition of Multidrug-Resistant Organisms (MDROs) With Pulsed-xenon (LAMP) Study: A Cluster-Randomized, Controlled, Double-Blinded, Interventional Crossover Trial.
    Clin Infect Dis. 2024;79:1024-1030.
    >> Share

  83. HICKEY MD, Gistand N, Grochowski J, Mayorga-Munoz F, et al
    48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia.
    Clin Infect Dis. 2024 Oct 5:ciae500. doi: 10.1093.
    >> Share

  84. INZAULE S, Easterbrook P, Latona A, Ford NP, et al
    Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2024 Oct 3:ciae431. doi: 10.1093.
    >> Share

  85. VIRK HS, Biemond JJ, Earny VA, Chowdhury S, et al
    Unraveling Sepsis Epidemiology in a Low- and Middle-Income Intensive Care Setting Reveals the Alarming Burden of Tropical Infections and Antimicrobial Resistance: A Prospective Observational Study (MARS-India).
    Clin Infect Dis. 2024 Oct 1:ciae486. doi: 10.1093.
    >> Share

    August 2024
  86. OGBUAGU O, Molina JM, Chetchotisakd P, Ramgopal MN, et al
    Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.
    Clin Infect Dis. 2024 Aug 29:ciae423. doi: 10.1093.
    >> Share

  87. GOODLET KJ, Nailor MD
    Central Nervous System Infections and Antibiotic Selection: All Infection Sites Are Not Created Equal.
    Clin Infect Dis. 2024;79:573-574.
    >> Share

  88. TAMMA PD, Heil EL, Justo JA, Mathers AJ, et al
    Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
    Clin Infect Dis. 2024 Aug 7:ciae403. doi: 10.1093.
    >> Share

    July 2024
  89. LJUNGMAN P, Chemaly RF, Khawaya F, Alain S, et al
    Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.
    Clin Infect Dis. 2024 Jul 23:ciae321. doi: 10.1093.
    >> Share

  90. BOUTIN CA, Durocher F, Beauchemin S, Ziegler D, et al
    Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.
    Clin Infect Dis. 2024;79:151-160.
    >> Share

  91. EUBANK TA, Dureja C, Garey KW, Hurdle JG, et al
    Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response.
    Clin Infect Dis. 2024;79:15-21.
    >> Share

  92. GROSSMAN MK, Rankin DA, Maloney M, Stanton RA, et al
    Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears.
    Clin Infect Dis. 2024;79:6-14.
    >> Share

  93. HEIL EL
    Put the Fluoroquinolone Down and No One Gets Hurt.
    Clin Infect Dis. 2024;79:1-2.
    >> Share

  94. GOTO M
    A Call for a Reinvention of Antibiogram.
    Clin Infect Dis. 2024;79:282.
    >> Share

    June 2024
  95. SENCHYNA F, Murugesan K, Rotunno W, Nadimpalli SS, et al
    Sequential Treatment Failure With Aztreonam-Ceftazidime-Avibactam Followed by Cefiderocol Due to Preexisting and Acquired Mechanisms in a New Delhi Metallo-beta-lactamase-Producing Escherichia coli Causing Fatal Bloodstream Infection.
    Clin Infect Dis. 2024;78:1425-1428.
    >> Share

  96. COOPER LN, Beauchamp AM, Ingle TA, Diaz MI, et al
    Socioeconomic Disparities and the Prevalence of Antimicrobial Resistance.
    Clin Infect Dis. 2024 Jun 7:ciae313. doi: 10.1093.
    >> Share

  97. SKRIVANKOVA VW, Huwa J, Muula G, Chiwaya GD, et al
    Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia.
    Clin Infect Dis. 2024 Jun 7:ciae261. doi: 10.1093.
    >> Share

    May 2024
  98. PINEDA-REYES R, Neil BH, Orndorff J, Williams-Bouyer N, et al
    Clinical presentation, antimicrobial resistance, and treatment outcomes of Aeromonas human infections: A 14-year retrospective study and comparative genomics of two isolates from fatal cases.
    Clin Infect Dis. 2024 May 17:ciae272. doi: 10.1093.
    >> Share

  99. GETANDA P, Jagne I, Bognini JD, Camara B, et al
    Impact of Intrapartum Azithromycin on the Carriage and Antibiotic Resistance of Escherichia coli and Klebsiella pneumoniae in Mothers and their Newborns: a sub-study of a Randomized Double-Blind Trial Conducted in The Gambia and Burkina Faso.
    Clin Infect Dis. 2024 May 16:ciae280. doi: 10.1093.
    >> Share

  100. WOLFE KH, Pierce VM, Humphries RM
    How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice.
    Clin Infect Dis. 2024;78:1140-1147.
    >> Share

  101. FALCONE M, Giordano C, Leonildi A, Galfo V, et al
    Clinical Features and Outcomes of Infections Caused by Metallo-beta-Lactamase-Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area.
    Clin Infect Dis. 2024;78:1111-1119.
    >> Share

  102. KONU YR, Takassi E, Peytavin G, Dapam N, et al
    Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo.
    Clin Infect Dis. 2024 May 15:ciae278. doi: 10.1093.
    >> Share

  103. PETERSON B, Arzika AM, Amza A, Maliki R, et al
    Assessment of spillover of antimicrobial resistance to untreated children 7 to 12 years old after mass drug administration of azithromycin for child survival in Niger: a secondary analysis of the MORDOR cluster-randomized trial.
    Clin Infect Dis. 2024 May 13:ciae267. doi: 10.1093.
    >> Share

    April 2024
  104. TAMMA PD, Immel S, Karaba SM, Soto CL, et al
    Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis with Sulbactam-Durlobactam.
    Clin Infect Dis. 2024 Apr 17:ciae210. doi: 10.1093.
    >> Share

  105. MARINER-LLICER C, Saavedra Cervera B, Mambuque E, Gomes N, et al
    Monitoring of First-line Drug Resistance Mutations Outside the Scope of Xpert MTB/RIF Ultra is Needed for Successful Control of DR-TB in Southern Mozambique.
    Clin Infect Dis. 2024;78:842-845.
    >> Share

  106. SHIELDS RK, Cheng WY, Kponee-Shovein K, Indacochea D, et al
    Development of Predictive Models to Inform a Novel Risk Categorization Framework for Antibiotic Resistance in E. coli-Causing Uncomplicated Urinary Tract Infection.
    Clin Infect Dis. 2024 Apr 4:ciae171. doi: 10.1093.
    >> Share

  107. TSCHUMI N, Lukau B, Tlali K, Motaboli L, et al
    Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho.
    Clin Infect Dis. 2024 Apr 3:ciae185. doi: 10.1093.
    >> Share

    March 2024

  108. Correction to: Capturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia (CAPTURA) Supplement.
    Clin Infect Dis. 2024 Mar 29:ciae122. doi: 10.1093.
    >> Share

  109. HAZRA A, Celum C, Luetkemeyer AF, Molina JM, et al
    Risk of antimicrobial resistance with doxy-PEP is real, as is the need for its well-Informed implementation.
    Clin Infect Dis. 2024 Mar 19:ciae152. doi: 10.1093.
    >> Share

  110. MOHANTY S, Ye G, Sheets C, Cossrow N, et al
    Association Between Social Vulnerability and Streptococcus pneumoniae Antimicrobial Resistance in US Adults.
    Clin Infect Dis. 2024 Mar 14:ciae138. doi: 10.1093.
    >> Share

  111. LANDOVITZ RJ, Tao L, Yang J, de Boer M, et al
    HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
    Clin Infect Dis. 2024 Mar 14:ciae143. doi: 10.1093.
    >> Share

    January 2024
  112. BONOMO RA, Perez F, Hujer AM, Hujer KM, et al
    The Real Crisis in Antimicrobial Resistance: Failure to Anticipate and Respond.
    Clin Infect Dis. 2024 Jan 30:ciad758. doi: 10.1093.
    >> Share

  113. VAN WELZEN BJ, Van Lelyveld SFL, Ter Beest G, Gisolf JH, et al
    Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis.
    Clin Infect Dis. 2024 Jan 11:ciae016. doi: 10.1093.
    >> Share

  114. URSENBACH A, Ruch Y, Hoellinger B, Fuchs A, et al
    Two cases of viral re-suppression after M184V + R263 K selection on DTG/3TC without treatment modification.
    Clin Infect Dis. 2024 Jan 9:ciae006. doi: 10.1093.
    >> Share

    December 2023
  115. VAN DER VAART TW, Prins JM, Goorhuis A, Lemkes BA, et al
    The utility of risk factors to define complicated Staphylococcus aureus bacteremia in a setting with low MRSA prevalence.
    Clin Infect Dis. 2023 Dec 29:ciad784. doi: 10.1093.
    >> Share

  116. POPOVICH KJ, Aureden K, Ham DC, Harris AD, et al
    Reply to Diekema et al. "Are contact precautions "essential" for the prevention of healthcare-associated methicillin-resistant Staphylococcus aureus?".
    Clin Infect Dis. 2023 Dec 20:ciad777. doi: 10.1093.
    >> Share

  117. SUJAN MJ, Habib ZH, Rahman A, Rizvi SMS, et al
    Antimicrobial Resistance Surveillance Methods in Bangladesh: Present and Way Forward.
    Clin Infect Dis. 2023;77.
    >> Share

  118. ABOUSHADY AT, Sujan MJ, Pham K, Clark A, et al
    Key Recommendations for Antimicrobial Resistance Surveillance: Takeaways From the CAPTURA Project.
    Clin Infect Dis. 2023;77.
    >> Share

  119. HOLM M, MacWright WR, Poudyal N, Shaw AG, et al
    Capturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia (CAPTURA).
    Clin Infect Dis. 2023;77.
    >> Share

  120. MAHARJAN S, Gallagher P, Gautam M, Joh HS, et al
    Recording and Reporting of Antimicrobial Resistance (AMR) Priority Variables and Its Implication on Expanding Surveillance Sites in Nepal: A CAPTURA Experience.
    Clin Infect Dis. 2023;77.
    >> Share

  121. TADESSE BT, Keddy KH, Rickett NY, Zhusupbekova A, et al
    Vaccination to Reduce Antimicrobial Resistance Burden-Data Gaps and Future Research.
    Clin Infect Dis. 2023;77.
    >> Share

  122. GALLAGHER P, Shaw A, Bhandari A, Poudyal N, et al
    Considerations for Expanding Antimicrobial Resistance Surveillance Networks.
    Clin Infect Dis. 2023;77.
    >> Share

  123. LESLIE T, Parry C, Ondoa P, Walsh T, et al
    The Reality of Antimicrobial Resistance and Antibiotic Usage Data in Asia: The CAPTURA Experience.
    Clin Infect Dis. 2023;77.
    >> Share

  124. JOH HS, Yeats C, Shaw A, Poudyal N, et al
    Methodological Approach to Identify and Expand the Volume of Antimicrobial Resistance (AMR) Data in the Human Health Sector in Low- and Middle-Income Countries in Asia: Implications for Local and Regional AMR Surveillance Systems Strengthening.
    Clin Infect Dis. 2023;77.
    >> Share

  125. JOH HS, Dolabella B, Early E, Stelling J, et al
    CAPTURA Regional Workshop Proceedings (28-30 June 2022, Virtual).
    Clin Infect Dis. 2023;77.
    >> Share

  126. POUDYAL N, Holm M, Joh HS, Gautam S, et al
    Effective Stakeholder Engagement for Collation, Analysis and Expansion of Antimicrobial Resistance (AMR) Data: A CAPTURA Experience.
    Clin Infect Dis. 2023;77.
    >> Share

  127. DOUD MB, Haste NM, Abeles SR
    Correspondence to Hasegawa et al. "Diagnostic Accuracy of Hospital Antibiograms in Predicting the Risk of Antimicrobial Resistance in Enterobacteriaceae Isolates: A Nationwide Multicenter Evaluation at the Veterans Health Administration".
    Clin Infect Dis. 2023 Dec 6:ciad748. doi: 10.1093.
    >> Share

  128. SANSOM SE, Gussin GM, Schoeny M, Singh RD, et al
    Rapid Environmental Contamination with Candida auris and Multidrug-Resistant Bacterial Pathogens Near Colonized Patients.
    Clin Infect Dis. 2023 Dec 6:ciad752. doi: 10.1093.
    >> Share

  129. NHU NTQ, Young VB
    The Relationship Between the Microbiome and Antimicrobial Resistance.
    Clin Infect Dis. 2023;77.
    >> Share

    November 2023
  130. MACDOUGALL C
    A Cloudy Crystal Ball: Critically Assessing and Rethinking the Antibiogram.
    Clin Infect Dis. 2023;77:1501-1503.
    >> Share

  131. MANHART LE, Leipertz G, Soge OO, Jordan SJ, et al
    Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions.
    Clin Infect Dis. 2023;77:1449-1459.
    >> Share

  132. MISRA K, Huang JS, Udeagu CN, Forgione L, et al
    Pre-exposure prophylaxis (PrEP) use history in people with antiretroviral resistance at HIV diagnosis: Findings from New York City HIV surveillance and partner services, 2015-2022.
    Clin Infect Dis. 2023 Nov 17:ciad699. doi: 10.1093.
    >> Share

  133. YASSIN A, Huralska M, Pogue JM, Dixit D, et al
    Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms.
    Clin Infect Dis. 2023;77:1223-1225.
    >> Share

  134. YASSIN A, Huralska M, Pogue JM, Dixit D, et al
    State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms.
    Clin Infect Dis. 2023;77:e46-e56.
    >> Share

  135. ASLAM S
    Phage Therapy in Lung Transplantation: Current Status and Future Possibilities.
    Clin Infect Dis. 2023;77.
    >> Share

    October 2023
  136. EVANS SR, Patel R, Hamasaki T, Howard-Anderson J, et al
    The Future Ain't What It Used to Be...Out With the Old...In With the Better: Antibacterial Resistance Leadership Group Innovations.
    Clin Infect Dis. 2023;77.
    >> Share

  137. CHAMBERS HF, Cross HR, Souli M, Evans SR, et al
    The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.
    Clin Infect Dis. 2023;77.
    >> Share

  138. CROSS HR, Greenwood-Quaintance KE, Souli M, Komarow L, et al
    Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group.
    Clin Infect Dis. 2023;77.
    >> Share

  139. HANSON KE, Banerjee R, Doernberg SB, Evans SR, et al
    Priorities and Progress in Diagnostic Research by the Antibacterial Resistance Leadership Group.
    Clin Infect Dis. 2023;77.
    >> Share

  140. SATLIN MJ, van Duin D, Tamma PD, Lodise TP, et al
    Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.
    Clin Infect Dis. 2023;77.
    >> Share

  141. JEZEK A, Del Rio C
    Antibacterial Resistance, Research, and Funding in 2024.
    Clin Infect Dis. 2023;77.
    >> Share

  142. HARRIS AD, Souli M, Pettigrew MM
    The Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group.
    Clin Infect Dis. 2023;77.
    >> Share

  143. DOERNBERG SB, Arias CA, Altman DR, Babiker A, et al
    Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.
    Clin Infect Dis. 2023;77.
    >> Share

  144. STRAUB TJ, Lombardo MJ, Bryant JA, Diao L, et al
    Impact of a purified microbiome therapeutic on abundance of antimicrobial resistance genes in patients with recurrent Clostridioides difficile infection.
    Clin Infect Dis. 2023 Oct 12:ciad636. doi: 10.1093.
    >> Share

    September 2023
  145. DIEKEMA DJ, Nori P, Stevens MP, Smith MW, et al
    Are contact precautions "essential" for the prevention of healthcare-associated methicillin-resistant Staphylococcus aureus?
    Clin Infect Dis. 2023 Sep 21:ciad571. doi: 10.1093.
    >> Share

  146. WANG M, Ge L, Chen L, Komarow L, et al
    Clinical Outcomes and Bacterial Characteristics of Carbapenem-Resistant Acinetobacter baumannii Among Patients from Different Global Regions.
    Clin Infect Dis. 2023 Sep 20:ciad556. doi: 10.1093.
    >> Share

  147. KASAIE P, Pennington J, Gupta A, Dowdy DW, et al
    The impact of preventive treatment for multidrug- and rifampin-resistant tuberculosis exceeds trial-based estimates.
    Clin Infect Dis. 2023 Sep 19:ciad557. doi: 10.1093.
    >> Share

  148. COTTO O, Armand-Lefevre L, Matheron S, Ruppe E, et al
    Within-Host Dynamics and Duration of Colonization of Travel-Acquired Multidrug-Resistant Enterobacterales in Untreated Individuals.
    Clin Infect Dis. 2023;77:934-936.
    >> Share

  149. BOAST A, How JA, Lau C, Sett A, et al
    Pre-XDR congenital tuberculosis in an extremely premature baby.
    Clin Infect Dis. 2023 Sep 8:ciad540. doi: 10.1093.
    >> Share

    August 2023
  150. HASEGAWA S, Livorsi DJ, Perencevich EN, Church JN, et al
    Diagnostic Accuracy of Hospital Antibiograms in Predicting the Risk of Antimicrobial Resistance in Enterobacteriaceae Isolates: A Nationwide Multicenter Evaluation at the Veterans Health Administration.
    Clin Infect Dis. 2023 Aug 10:ciad467. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016